A cost-effectiveness analysis of typhoid fever vaccines in US military personnel.
Typhoid fever has been a problem for military personnel throughout history. A cost-effectiveness analysis of typhoid fever vaccines from the perspective of the US military was performed. Currently 3 vaccine preparations are available in the US: an oral live Type 21A whole cell vaccine; a single-dose parenteral, cell subunit vaccine; and a 2-dose parenteral heat-phenol killed, whole cell vaccine. This analysis assumed all vaccinees were US military personnel. Two pharmacoeconomic models were developed, one for personnel who have not yet been deployed, and the other for personnel who are deployed to an area endemic for typhoid fever. Drug acquisition, administration, adverse effect and lost work costs, as well as the costs associated with typhoid fever, were included in this analysis. Unique military issues, typhoid fever attack rates, vaccine efficacy, and compliance with each vaccine's dosage regimen were included in this analysis. A sensitivity analysis was performed to test the robustness of the models. Typhoid fever immunisation is not cost-effective for US military personnel unless they are considered imminently deployable or are deployed. The most cost-effective vaccine for US military personnel is the single-dose, cell subunit parenteral vaccine.
Warren
T A
TA
Wilford Hall Medical Center, Department of Pharmacy, Lackland Air Force Base, Texas, USA. warren_t@whmc-lafb.af.mil
Finder
S F
SF
Brier
K L
KL
Ries
A J
AJ
Weber
M P
MP
Miller
M R
MR
Potyk
R P
RP
Reeves
C S
CS
Moran
E L
EL
Tornow
J J
JJ
D003362:Cost-Benefit Analysis / Q000191:economics*; D006801:Humans; D008889:Military Personnel; D014435:Typhoid Fever / Q000517:prevention & control*; D014481:United States; D014612:Vaccines / Q000191:economics*